Cantor Fitzgerald initiated coverage on Arcellx
$ACLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $109.00 | Buy | Redburn Atlantic |
| 9/3/2024 | Overweight | Cantor Fitzgerald | |
| 5/31/2024 | $70.00 | Overweight | Piper Sandler |
| 3/7/2024 | $81.00 | Overweight | Morgan Stanley |
| 1/4/2024 | $65.00 → $71.00 | Buy | Needham |
| 12/19/2023 | $66.00 | Sector Outperform | Scotiabank |
| 10/30/2023 | Outperform | TD Cowen | |
| 10/17/2023 | $52.00 | Buy | UBS |
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced two upcoming investor events: TD Cowen's 6th Annual Oncology Innovation Summit Tuesday, May 27, 2025 at 9:00 a.m. PT (Virtual) Management and Physician Presentation and Discussion of iMMagine-1 Pivotal Study Results During EHA2025 Friday, June 13, 2025 at 8:30 p.m. CEST (Virtual and In-Person, Milan, Italy) A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 3
-- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months -- -- No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel -- -- iMMagine-1 data to be presented during an oral presentation at EHA2025 on Saturday, June 14, 2025 -- -- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies f
-- iMMagine-1 data accepted for Oral Presentation at EHA -- -- iMMagine-3 study updated to include MRD negativity as a dual primary endpoint -- -- Added two new Board members with commercial and operational expertise -- -- Ended the quarter with $565M in cash, which is expected to fund operations into 2028 -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. "Delivering therapies that can positively impact patients' lives is our mission," said Rami Elg
-- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market
REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters.
FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. -- -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma -- -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
Redburn Atlantic initiated coverage of Arcellx with a rating of Buy and set a new price target of $109.00
Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight
Piper Sandler initiated coverage of Arcellx with a rating of Overweight and set a new price target of $70.00
8-K - Arcellx, Inc. (0001786205) (Filer)
SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)
8-K - Arcellx, Inc. (0001786205) (Filer)
SC 13G - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)